Mirum Pharmaceuticals, Inc. (MIRM)

NASDAQ: MIRM · IEX Real-Time Price · USD
23.49
-0.54 (-2.23%)
May 18, 2022 12:38 PM EDT - Market open
Market Cap747.65M
Revenue (ttm)32.03M
Net Income (ttm)-70.06M
Shares Out31.84M
EPS (ttm)-2.77
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume34,722
Open23.74
Previous Close24.02
Day's Range23.16 - 24.36
52-Week Range12.82 - 28.65
Beta1.39
AnalystsBuy
Price Target57.85 (+146.3%)
Earnings DateMay 5, 2022

About MIRM

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, I...

IndustryBiotechnology
IPO DateJul 18, 2019
Employees137
Stock ExchangeNASDAQ
Ticker SymbolMIRM
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for MIRM stock is "Buy." The 12-month stock price forecast is 57.85, which is an increase of 146.33% from the latest price.

Price Target
$57.85
(146.33% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

1 week ago - Business Wire

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q1 Loss, Tops Revenue Estimates

Mirum Pharmaceuticals, Inc. (MIRM) delivered earnings and revenue surprises of 15.83% and 48.59%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

1 week ago - Zacks Investment Research

Mirum Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update

1 week ago - Business Wire

Mirum Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Conference Call on May 5, 2022

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report first quarter financial results on Thursday, May 5, 2022. That same day, Mirum will h...

2 weeks ago - Business Wire

Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business Update

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business Update

2 months ago - Business Wire

Why Earnings Season Could Be Great for Mirum Pharmaceuticals (MIRM)

Mirum Pharmaceuticals (MIRM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

2 months ago - Zacks Investment Research

Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End Business Results for 2021 and Host Conference Call on M...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End Business Results for 2021 and Host Conference Call on March 9, 2022

2 months ago - Business Wire

Mirum Pharmaceuticals to Present at SVB Leerink 11th Annual Global Healthcare Conference

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Present at SVB Leerink 11th Annual Global Healthcare Conference

3 months ago - Business Wire

Mirum Pharmaceuticals Provides Business Update and Highlights Key 2022 Corporate Milestones

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Provides Business Update and Highlights Key 2022 Corporate Milestones

4 months ago - Business Wire

Mirum Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022

4 months ago - Business Wire

Mirum Pharmaceuticals Added to NASDAQ Biotechnology Index

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Added to NASDAQ Biotechnology Index

5 months ago - Business Wire

LIVMARLI (maralixibat) Presentations Show Improvements in Quality of Life Measures in Alagille Syndrome and PFIC2 at ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--LIVMARLI (maralixibat) Presentations Show Improvements in Quality of Life Measures in Alagille Syndrome and PFIC2 at NASPGHAN Annual Meeting 2021

5 months ago - Business Wire

Mirum Pharmaceuticals to Present LIVMARLI™ (maralixibat) Analyses at NASPGHAN 2021 Annual Meeting

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Present LIVMARLI™ (maralixibat) Analyses at NASPGHAN 2021 Annual Meeting

5 months ago - Business Wire

Moore Kuehn, PLLC Encourages Investors of Mirum Pharmaceuticals, Inc. to Contact Law Firm

New York, New York--(Newsfile Corp. - November 30, 2021) - Moore Kuehn, PLLC, a securities law firm located on Wall Street , is investigating whether certain officers and directors of Mirum Pharmaceutic...

5 months ago - Newsfile Corp

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

5 months ago - Business Wire

Mirum Pharmaceuticals Sells Rare Pediatric Disease Priority Review Voucher

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Sells Rare Pediatric Disease Priority Review Voucher

6 months ago - Business Wire

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q3 Loss

Mirum Pharmaceuticals, Inc. (MIRM) delivered earnings and revenue surprises of 4.91% and 0.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the s...

6 months ago - Zacks Investment Research

Mirum Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update

6 months ago - Business Wire

Six-Year Natural History Comparison with Mirum's LIVMARLI (maralixibat) Demonstrates Event-Free Survival and Transpla...

FOSTER CITY, Calif.--(BUSINESS WIRE)--6-Year Natural History Comparison with Mirum's LIVMARLI Demonstrates Event-Free Survival and Transplant-Free Survival in Patients with ALGS

6 months ago - Business Wire

Mirum Pharmaceuticals to Report Third Quarter 2021 Financial Results and Host Conference Call on November 15, 2021

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Report Third Quarter 2021 Financial Results and Host Conference Call on November 15, 2021

6 months ago - Business Wire

New LIVMARLI™ (maralixibat) Data to be Showcased at AASLD The Liver Meeting® 2021

FOSTER CITY, Calif.--(BUSINESS WIRE)--New LIVMARLI™ (maralixibat) Data to be Showcased at AASLD The Liver Meeting® 2021

6 months ago - Business Wire

The Lancet Publishes Data From Mirum Pharmaceuticals' ICONIC Pivotal Study of Maralixibat (LIVMARLI) Treatment in Ala...

FOSTER CITY, Calif.--(BUSINESS WIRE)--The Lancet Publishes Data from the ICONIC Pivotal Study of Maralixibat (LIVMARLI) Treatment in Alagille Syndrome

6 months ago - Business Wire

Mirum's treatment for a rare liver disorder gets FDA approval

Shares of Mirum Pharmaceuticals Inc. MIRM, -0.43% gained 2.3% in premarket trading on Thursday, the day after the company announced that the Food and Drug Administration had approved Livmarli as a treat...

7 months ago - Market Watch

FDA Approves First Treatment For Alagille Syndrome-Associated Cholestatic Pruritus From Mirum Pharma

The FDA has approved Mirum Pharmaceuticals Inc (NASDAQ: MIRM) Livmarli (maralixibat) oral solution for cholestatic pruritus in patients with Alagille syndrome (ALGS) one year of age and older.  Livmarli...

7 months ago - Benzinga

U.S. FDA Approves LIVMARLI (maralixibat) as the First and Only Approved Medication for the Treatment of Cholestatic P...

FOSTER CITY, Calif.--(BUSINESS WIRE)--FDA Approves LIVMARLI as the First and Only Approved Medication for the Treatment of Cholestatic Pruritus in Patients with ALGS

7 months ago - Business Wire